# Adaptimmune

its TCR-T product Tecelra (afamitresgene autoleucel) targets MAGE-A4 in synovial sarcoma and was the first engineered-TCR cell therapy approved, anchoring the autologous TCR-T class alongside pipeline assets lete-cel (NY-ESO-1) and other MAGE-A4/PRAME programmes.

Source: https://en.bioecon.ru/companies/adaptimmune/
Updated: 2026-07-11

- Country: United Kingdom
- Ticker: ADAP

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $55 million upfront payment from US WorldMeds plus up to $30 million in milestone payments, following the sale of its cell therapy assets (TECELRA, lete-cel, afami-cel, uza-cel) in July 2025 | https://www.adaptimmune.com/investors-and-media/sec-filings/all-sec-filings/content/0001104659-25-071009/tm2521829d1_8k.htm, https://www.sec.gov/Archives/edgar/data/1621227/000155837025011304/adap-20250813xex99d1.htm, https://www.sec.gov/Archives/edgar/data/1621227/000155837025011307/R25.htm |
| Capacity | Commercial manufacturing success rate of 100% with no constraints as of the second quarter of 2025 | https://www.adaptimmune.com/investors-and-media/sec-filings/all-sec-filings/content/0001558370-25-003544/0001558370-25-003544.pdf, https://www.newsfilecorp.com/release/245279/Adaptimmune-Provides-Q4-and-Full-Year-2024-Business-Update, https://www.sec.gov/Archives/edgar/data/1621227/000155837025011304/adap-20250813xex99d1.htm |
| Regulatory approval | TECELRA (afamitresgene autoleucel) received U.S. FDA accelerated approval on August 1, 2024 for adults with unresectable or metastatic synovial sarcoma | https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/271/adaptimmune-receives-u-s-fda-accelerated-approval-of, https://www.adaptimmune.com/investors-and-media/sec-filings/all-sec-filings/content/0001558370-25-003544/0001558370-25-003544.pdf, https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-tecelra-synovial-sarcoma-mage-a4, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-afamitresgene-autoleucel-unresectable-or-metastatic-synovial-sarcoma |
| Production site | Facilities in Philadelphia, Boston, and the United Kingdom | https://www.adaptimmune.com/investors-and-media/sec-filings/all-sec-filings/content/0001558370-25-003544/0001558370-25-003544.pdf, https://www.newsfilecorp.com/release/245279/Adaptimmune-Provides-Q4-and-Full-Year-2024-Business-Update |
| Headcount | Reduced workforce by approximately 29% in the first quarter of 2025 and planned a further reduction of approximately 62% of the remaining workforce following the July 2025 transaction | https://www.adaptimmune.com/investors-and-media/sec-filings/all-sec-filings/content/0001104659-25-071009/tm2521829d1_8k.htm, https://www.adaptimmune.com/investors-and-media/sec-filings/all-sec-filings/xbrl_doc_only/2590, https://www.sec.gov/Archives/edgar/data/1621227/000155837025011304/adap-20250813xex99d1.htm |
| Revenue | Product revenue of $11.1 million for the second quarter of 2025; total revenue of $13.7 million for the same period | https://www.sec.gov/Archives/edgar/data/1621227/000155837025011304/adap-20250813xex99d1.htm |

Independent sources: cancer.gov, fda.gov, newsfilecorp.com, sec.gov

## Technologies

- [TCR therapy (T-cell receptor engineered T cells)](https://en.bioecon.ru/technology/tcr-therapy/)